BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. Financial performance shows increased net loss and cash usage, which are negative. However, there are ongoing advancements in trials and partnerships, which are positive. The Q&A highlights uncertainties around regulatory approvals and partnerships, but also potential growth opportunities. The neutral sentiment reflects this balance of positive developments against financial challenges and uncertainties.
Key Financial Performance
Research and Development Expenses (Q2 2025) Increased to approximately $1.4 million from approximately $0.8 million in Q2 2024, a 75% increase. The increase was driven by closeout activities including data analysis for the CardiAMP Heart Failure trial, enrollment in the CardiAMP Heart Failure II trial, and regulatory activities in Japan.
Research and Development Expenses (6 months ended June 2025) Increased to approximately $2.9 million from $2.0 million in the 6 months ended June 2024, a 45% increase. The reasons for the increase are similar to those for Q2 2025.
Selling, General and Administrative Expenses (Q2 2025) Decreased to approximately $0.7 million from approximately $0.9 million in Q2 2024, a 22% decrease. This was primarily due to lower professional fees and share-based compensation expense.
Selling, General and Administrative Expenses (6 months ended June 2025) Remained consistent at approximately $1.9 million compared to the same period in 2024. No significant changes were noted.
Net Loss (Q2 2025) Increased to approximately $2.0 million from approximately $1.6 million in Q2 2024, a 25% increase. The increase was attributed to higher research and development expenses.
Net Loss (6 months ended June 2025) Increased to approximately $4.8 million from approximately $3.9 million in the 6 months ended June 2024, a 23% increase. The increase was attributed to higher research and development expenses.
Net Cash Used in Operations (Q2 2025) Increased to approximately $1.6 million from approximately $1.3 million in Q2 2024, a 23% increase. This was driven by the increase in research and development expenses.
Net Cash Used in Operations (6 months ended June 2025) Increased to approximately $3.3 million from approximately $2.8 million in the 6 months ended June 2024, a 17.9% increase. This was driven by the increase in research and development expenses.
Cash and Cash Equivalents (End of Q2 2025) Totaled $980,000. After selling $769,000 in common stock in Q3 2025, the cash balance increased to approximately $1.1 million, providing runway into October 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CardiAMP Heart Failure trial: Completed trial with significant findings, including lower incidence of all-cause death and nonfatal MACE in treatment group. Data submitted to Japan's PMDA for potential approval.
Helix biotherapeutic delivery system: Preparing for FDA submission for approval via de novo 510(k) pathway. Potential to be the first approved transendocardial biotherapeutic delivery system in the U.S.
Morph DNA steerable introducer platform: Proprietary FDA-approved platform being positioned for partnerships in the cardiac electrophysiology market.
Japan market: Engaging with Japan's PMDA for approval of CardiAMP system. Japan has a strong interest in heart failure therapies.
Cardiac electrophysiology market: Exploring partnerships for Morph DNA platform in a market valued at over $10 billion annually.
R&D expenses: Increased to $1.4 million in Q2 2025 due to trial closeout activities and regulatory efforts in Japan.
SG&A expenses: Decreased to $0.7 million in Q2 2025 due to lower professional fees and share-based compensation.
Partnerships: Actively pursuing partnerships for CardiAMP, CardiALLO, Helix, and Morph DNA platforms to enhance shareholder value.
Financing: Planning a financing round in September 2025 to support operations and shareholder interests.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company faces uncertainties in obtaining regulatory approvals for its CardiAMP Heart Failure therapy in both Japan and the United States. Delays or misalignment with regulatory agencies like Japan's PMDA or the FDA could impact market entry timelines and revenue generation.
Financial Stability: The company reported a net loss of $2.0 million for Q2 2025 and has limited cash reserves of $1.1 million, providing runway only into October 2025. This financial strain could hinder ongoing operations and R&D activities if additional funding is not secured.
R&D Expenses: Research and development expenses have increased significantly, driven by trial closeout activities and regulatory efforts. This rise in costs could strain financial resources further, especially given the company's limited cash reserves.
Market Competition: The company anticipates two other cardiac cell therapies to be considered for approval by Japan's PMDA in the coming year. This competitive landscape could limit market share and partnership opportunities for BioCardia's CardiAMP therapy.
Partnership Dependencies: The company is heavily reliant on partnerships for its Helix biotherapeutic delivery system and other platforms. Delays or failures in securing these partnerships could impact commercialization and revenue streams.
Operational Costs: Increased operational costs, including R&D and regulatory activities, are contributing to higher cash burn rates. This could pose a risk to the company's financial health if not managed effectively.
Funding Risks: The company is planning a financing round in September 2025, but its success is uncertain. Failure to secure adequate funding could jeopardize ongoing projects and strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
CardiAMP Heart Failure Therapy: BioCardia plans to align with Japan's PMDA in Q4 2025 for potential approval of the CardiAMP system for market entry in Japan. Concurrently, they aim to meet with the FDA in Q4 2025 to discuss the approvability of the CardiAMP system based on clinical data. The CardiAMP Heart Failure II trial is actively enrolling patients, with a fifth site activation expected soon.
CardiAMP Cell Therapy for Chronic Myocardial Ischemia (BCDA-02): Final top-line data from the roll-in cohort is expected in Q4 2025, with plans for peer-reviewed publication of the results.
CardiALLO Allogeneic Mesenchymal Stem Cell Therapy (BCDA-03): Non-dilutive funding is anticipated in Q1 2026 to support this program.
Helix Biotherapeutic Delivery System: FDA submission for approval is anticipated in Q3 2025. The system has potential to be the first approved transendocardial biotherapeutic delivery system in the U.S. BioCardia is actively seeking partnerships for this technology.
Morph DNA Steerable Introducer Platform: Partnership discussions are ongoing for applications in the cardiac electrophysiology market, which exceeds $10 billion annually.
Business Development and Partnerships: BioCardia is focused on partnerships across its platforms (CardiAMP, CardiALLO, Helix, and Morph DNA) to enhance shareholder value. They are actively engaging with potential partners for biotherapeutic delivery and cardiac electrophysiology applications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you elaborate on the expectations regarding PMDA reviewing CardiAMP for heart failure as a medical device?
A:The approval process for CardiAMP in Japan is considered a lower hurdle compared to other medical devices since it leaves nothing behind in the patient. The PMDA consultation process involves clinical data and therapy positioning in heart failure care. CardiAMP aligns with Japanese cultural preferences for autologous therapies and fits into existing medical device distribution channels. Japan has a significant need for heart failure therapies due to low heart transplantation rates and high mortality rates. PMDA may request post-marketing studies to gather additional safety and efficacy data.
Q:Are the rolling core data anticipated in the fourth quarter related to the primary endpoint results at 6 months?
A:Yes, the rolling core data anticipated in the fourth quarter are related to the primary endpoint results at 6 months.
Q:What would the timing look like if the regulatory meetings in Japan and the U.S. go well?
A:If the PMDA and FDA meetings go well, the approval process could take up to a year, including audits and detailed reviews. In Japan, the focus would shift to reimbursement and distribution partnerships. For the FDA, the Helix system will be submitted first, followed by CardiAMP Heart Failure. Post-marketing requirements are expected in both regions.
Q:Are partnerships on hold until clarity on FDA and PMDA approvals?
A:No, partnerships are not on hold. While CardiAMP partnerships depend on regulatory clarity, active discussions are ongoing for other technology platforms like Helix and Morph. Distribution partnerships in Japan are also being explored.
Q:What type of meeting will the FDA meeting be, and what is the status of the HF II trials?
A:The type of FDA meeting (Type B or Type C) has not been decided. CardiAMP HF II trials have 4 active centers, with a fifth starting soon. Patients are being observed for a month before baseline measures to account for the Hawthorne effect. The trial focuses on patients with elevated NT-proBNP and has Medicare reimbursement in place.
Q:Will clarity from PMDA and FDA be available by the end of Q4?
A:Clarity from PMDA is expected by the end of Q4, but FDA clarity will follow later as the Helix system submission precedes CardiAMP discussions.
Q:What are the expectations following the data readout for BCDA-02?
A:The BCDA-02 program is positioned for partnering discussions. If PMDA or FDA approvals for CardiAMP are favorable, resources could be allocated to accelerate BCDA-02. The program offers a low-cost therapy compared to competitors and has shown promising results.
Q:Will new data observations submitted to PMDA be released to the public?
A:Some new data observations will be included in a peer-reviewed manuscript for public access, but certain details may remain exclusive to regulatory submissions.
Q:How will the September financing event benefit shareholders?
A:The company aims to secure financing with minimal dilution, focusing on long-term holders. The burn rate is low, and the company is prioritizing non-dilutive capital to fund its programs.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer on the type of FDA meeting (Type B or Type C) for CardiAMP discussions, stating that the decision is still under consideration. Additionally, while they mentioned active partnering discussions, specific details or timelines for these partnerships were not provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agency PMDA
BCDA CardiALLO
BCDA program
Benvenuti Corporate
BioCardia approval
CEO parallel
CardiALLO mesenchymal
CardiAMP Heart
CardiAMP cell
CardiAMP system
Cardiology session
Cardium system
Co LLC
Conference ET
Corporate Participant
DNA technology
Director Francis
FDA approvability
Failure trial
LLC Research
McClung Chief
Research Division
ablation
catheter
death
electrophysiology market
financing
funding
meeting
patient disease
peer manuscript
potential
study
submission approval
therapy CardiAMP
BCDA Transcript
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call shows a mixed picture: a 25% revenue increase and improved net loss are positive, but the inherent regulatory and product development risks pose concerns. The absence of strategic initiatives and shareholder return discussions limits the positive impact. Cash reserves have decreased, but cost controls are in place. The lack of market cap data prevents assessment of stock sensitivity. Overall, the sentiments are balanced, leading to a neutral prediction for stock movement.
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reveals mixed sentiments: increased R&D expenses and operational costs are concerning, but the CardiAMP HF's potential FDA approval and competitive advantage offer optimism. The Q&A highlights slow trial enrollment and non-significant p-values, but also potential regulatory success and partnership interest. The absence of strong financial guidance and the challenge of rising costs balance the positive aspects, leading to a neutral outlook for the stock price over the next two weeks.
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call shows mixed signals: a slight increase in revenue, reduced SG&A expenses, and a decrease in net loss for Q3, but an increase in net loss over nine months. The Q&A reveals positive progress in trials but lacks transparency in patient enrollment numbers. The strategic plan highlights potential partnerships and regulatory approvals, which could be positive. However, the absence of market cap data and the lack of immediate strong catalysts lead to a neutral outlook for short-term stock movement.
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
Unknown8-11
The earnings call reveals mixed signals. Financial performance shows increased net loss and cash usage, which are negative. However, there are ongoing advancements in trials and partnerships, which are positive. The Q&A highlights uncertainties around regulatory approvals and partnerships, but also potential growth opportunities. The neutral sentiment reflects this balance of positive developments against financial challenges and uncertainties.
BCDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
